Journal
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE
Volume 9, Issue 3, Pages 261-267Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SPC.0000000000000157
Keywords
bone metastasis; denosumab; prostate cancer; radium-223; zoledronic acid
Categories
Funding
- Amgen
- Novartis
- Bayer
Ask authors/readers for more resources
Purpose of review Bone metastases in the advanced stages of prostate cancer have a detrimental effect on the quality of life, resulting in skeletal-related events and pain and place a significant burden on healthcare resources. Improvements in prostate cancer treatment have led to a longer survival of patients. Therefore, quality of life is of growing interest and importance. Successful management and prevention of the complications of bone metastasis in those patients remains, however, clinically challenging. Recent findings Recently, radium-223 was approved as a treatment for bone metastasis in patients with prostate cancer, joining zoledronic acid, denosumab and other radiopharmaceuticals in the clinical armamentarium. Radium-223 has shown to improve overall survival in patients with bone metastasis. Summary This review focuses on the recent landmark studies on zoledronic acid, denosumab and radium-223 for patients with metastatic prostate cancer and gives a comprehensive overview of their mechanism of action, efficacy, dosage and safety profile.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available